149 related articles for article (PubMed ID: 28398382)
1. [Use of rivaroxaban in real-life treatment of venous thromboembolism: results of the TEV Survey, an Italian epidemiological study].
Pesavento R; Iori I;
G Ital Cardiol (Rome); 2017 Mar; 18(3):239-246. PubMed ID: 28398382
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
[TBL] [Abstract][Full Text] [Related]
3. Patterns and Predictors of Use of Anticoagulants for the Treatment of Venous Thromboembolism Following Approval of Rivaroxaban.
Dault R; Vanasse A; Blais L; Perreault S; Farand P; Le Templier G; Beauchesne MF
Clin Appl Thromb Hemost; 2016 Nov; 22(8):765-771. PubMed ID: 26467323
[TBL] [Abstract][Full Text] [Related]
4. Practical management of rivaroxaban for the treatment of venous thromboembolism.
Imberti D; Benedetti R
Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
[TBL] [Abstract][Full Text] [Related]
5. A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism.
Kabuki T; Nakanishi R; Hisatake S; Fujii T; Dobashi S; Wakakura S; Kiuchi S; Fujino T; Ikeda T
J Cardiol; 2017 Aug; 70(2):163-168. PubMed ID: 27979674
[TBL] [Abstract][Full Text] [Related]
6. Real-Life Management of Venous Thromboembolism With Rivaroxaban: Results From EXperience VTE, an Italian Epidemiological Survey.
Imberti D; Barillari G;
Clin Appl Thromb Hemost; 2018 Mar; 24(2):241-247. PubMed ID: 28718296
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach.
Arcelus JI; Domènech P; Fernández-Capitan Mdel C; Guijarro R; Jiménez D; Jiménez S; Lozano FS; Monreal M; Nieto JA; Páramo JA
Clin Appl Thromb Hemost; 2015 May; 21(4):297-308. PubMed ID: 25504999
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes.
Gaertner S; Cordeanu EM; Nouri S; Faller AM; Frantz AS; Mirea C; Bilbault P; Ohlmann P; Le Ray I; Stephan D
Int J Cardiol; 2017 Jan; 226():103-109. PubMed ID: 27806307
[TBL] [Abstract][Full Text] [Related]
9. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
10. Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry.
Keller L; Marten S; Hecker J; Sahin K; Tittl L; Beyer-Westendorf J
Int J Cardiol; 2018 Apr; 257():276-282. PubMed ID: 29506708
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: A Single-Center Registry.
Bott-Kitslaar DM; Saadiq RA; McBane RD; Loprinzi CL; Ashrani AA; Ransone TR; Wolfgram AA; Berentsen MM; Wysokinski WE
Am J Med; 2016 Jun; 129(6):615-9. PubMed ID: 26797081
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
Kucher N; Aujesky D; Beer JH; Mazzolai L; Baldi T; Banyai M; Hayoz D; Kaeslin T; Korte W; Escher R; Husmann M; Frauchiger B; Baumgartner I; Spirk D
Thromb Haemost; 2016 Aug; 116(3):472-9. PubMed ID: 27346301
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban for treatment of venous thromboembolism in older adults.
Mitchell AP; Conway SE
Consult Pharm; 2014 Sep; 29(9):627-30. PubMed ID: 25203412
[TBL] [Abstract][Full Text] [Related]
14. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
Cohen AT; Dobromirski M
Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
[TBL] [Abstract][Full Text] [Related]
15. [Real life clinical management of nonvalvular atrial fibrillation: results from the Italian epidemiological survey eXperience on the use of rivaroxaban].
Colonna P; Ammirati F;
G Ital Cardiol (Rome); 2016 Nov; 17(11):932-939. PubMed ID: 27996999
[TBL] [Abstract][Full Text] [Related]
16. The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
Patel AA; Ogden K; Mody SH; Bookhart B
J Med Econ; 2015 May; 18(5):323-32. PubMed ID: 25557176
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban for the treatment of venous thromboembolism in real life: A single-center prospective study.
Demelo-Rodríguez P; Galeano-Valle F; García-Fernández-Bravo I; Piqueras-Ruiz S; Álvarez-Sala-Walther L; Del Toro-Cervera J
Medicine (Baltimore); 2019 Jan; 98(3):e14093. PubMed ID: 30653127
[TBL] [Abstract][Full Text] [Related]
18. Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience.
Arachchillage D; Reynolds R; Devey T; Maclean R; Kitchen S; van Veen JJ
Thromb Res; 2016 Nov; 147():32-35. PubMed ID: 27669125
[No Abstract] [Full Text] [Related]
19. Multidisciplinary approach to the management of patients with pulmonary embolism and deep vein thrombosis: a consensus on diagnosis, traditional therapy and therapy with rivaroxaban.
Imberti D; Becattini C; Bernardi E; Camporese G; Cuccia C; Dentali F; Paretti D
Intern Emerg Med; 2018 Oct; 13(7):1037-1049. PubMed ID: 29520700
[TBL] [Abstract][Full Text] [Related]
20. Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies.
Choe HK; De Sancho MT; Kim SS; Dai T; Shah MA
Blood Coagul Fibrinolysis; 2018 Mar; 29(2):227-230. PubMed ID: 29389673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
